Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950347 | 0.81 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4719490 | 0.77 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL13387564 | 0.77 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL28019672 | 0.75 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL26677284 | 0.74 | EPHX1 (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL1827279 | 0.74 | EPHX1 (0.64) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| SCHEMBL22801974 | 0.73 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3332407 | 0.73 | NAAA (0.52) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL2801497 | 0.73 | EPHX1 (0.67) | GAAMAPK1HTTSMN1; SMN2EPHX1 | |
| Acetic Acid SCHEMBL4473079 | 0.73 | NAAA (0.49) | GAAMAPK1HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | GAA 4060/4885MAPK1 3052/4885HTT 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.